Intrathecal topotecan in adult patients with neoplastic meningitis

American Journal of Health-System Pharmacy

Volumn 63, Issue 21, 2006, Pages 2083-2086

  Gammon, David C ^a   Bhatt, Mansi S ^b   Tran, Lan ^c   Van Horn, Alexis ^b   Benvenuti, Matthew ^b   Glantz, Michael J ^b  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

^b UC   (United States)

^c MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Antineoplastic agents; Drug administration routes; Meningeal neoplasms; Topotecan; Toxicity

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; GEFITINIB; LOMUSTINE; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; TOPOTECAN;

ADULT; ANOREXIA; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CYTOLOGY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; MALAISE; MALE; MENINGIOMA; MENINGITIS; NAUSEA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; REVIEW; VOMITING;

EID: 33751058418     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060165     Document Type: Review

References (14)

1. Central Brain Tumor Registry of the United States. 2004-2005 Primary brain tumors in the United States, statistical report, 1997-2001. www.cbtrus.org/reports//2004-2005/2005report.pdf (accessed 2006 Aug 6).
2. Ahmedin J, Taylor M, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55:10-30.
3. Patchell RA. The management of brain metastases. Cancer Treat Rev. 2003; 29:533-40.
4. Larson DA, Rubenstein JL, McDermott MW. Metastatic brain cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:2323-35.
5. National Cancer Institute. Adult brain tumors (PDQ): treatment, www.cancer.gov/cancertopics/pdq/treatment/adultbrain/healthprofessional (accessed 2005 Nov 12).
6. Chamberlain MC. Neoplastic meningitis. J Clin Oncol. 2005; 23:3605-13.
7. Sneed PK, Huang K, Rubenstein JL. Brain metastases and carcinomatous meningitis. Chap. 56. In: Abeloff MD, Armitage JO, Niederhuber JE et al., eds. Clinical oncology, 3rd ed. New York: Churchill Livingstone; 2004:1073-85.
8. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005; 23:6207-19.
9. Strother DR, Glynn-Barnhart A, Kovner E. Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. J Clin Oncol. 1989; 7:1741-7.
10. Wong ET, Berkenblit A. The role of topotecan in the treatment of brain metastases. Oncologist. 2004; 9:68-79.
11. Blaney SM, Cole DE, Godwin L et al. Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol. 1995; 36:121-4.
12. Blaney SM, Heideman R, Berg S et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003; 21:143-7.
13. Glantz MJ, Cole BF, Glantz LK et al. Cerebrospinal fluid cytology in patient with cancer: how to minimize false negative results. Cancer. 1998; 82:733-9.
14. Glantz MJ, Jaeckle K, Chamberlain MC et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999; 5:3394-402.